Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients.
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2013
At a glance
- Drugs Givinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Italfarmaco
- 07 Aug 2012 Planned number of patients changed from 5 to 23 as reported by European Clinical Trials Database.
- 01 Feb 2012 Actual patients number is 19 as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.